Skip to main content
. Author manuscript; available in PMC: 2023 Nov 30.
Published in final edited form as: Clin Cancer Res. 2023 Aug 1;29(15):2767–2773. doi: 10.1158/1078-0432.CCR-23-0112

Table 2.

Treatment response.

During cycles 1–2 of 17β-estradiola During alternating Txa
n (%) n (%)
Best response by RECIST
 PR
2 (10.5)b 3 (15.8)b
 SD 12 (63.2) 5 (26.3)
 Disease progression 5 (26.3) 11 (57.9)
 Total evaluable 19 (100.0) 19 (100.0)
Clinical benefitc 8 (42.1)
a

Response as measured compared with baseline.

b

One PR was nonconfirmed.

c

Defined as SD ≥ 24 weeks or PR.